Search TRDA
Entrada Therapeutics, Inc.
Nasdaq · CIK 1689375
Last close5.38
Daily change-0.30 (-5.28%)
10 Years gain-77.54%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
TRDA · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
27.5Momentum
0.0Acceleration
0.0Confidence
69.0Annual Revenue3
Quarterly Revenue14
Annual CFO6
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth0.0 / 25
Quality12.5 / 25
Capital Efficiency0.0 / 20
Balance Sheet15.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Net debt reductionNet debt declined versus the comparison period.
Warnings
Operating margin compression · MEDIUMOperating margin compressed by 3410.5583 percentage points.
ROIC declining · MEDIUMROIC declined by 59.9382 percentage points.
Key Metrics
Revenue Growth TTM-97.25%OK
Revenue CAGR 3Yn/aINSUFFICIENT_HISTORY
Gross Margin100%OK
Operating Margin-3,394.53%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-51.91%OK
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y2.79%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $25.42M | $25.42M | -$157.90M | -$128.51M | -$129.55M | 100% | -621.13% | -509.63% | -45.93% | 41.37M |
| 2025 FY Dec 31, 2024 | $210.78M | $210.78M | $47.01M | -$41.56M | -$44.72M | 100% | 22.3% | -21.21% | 14.79% | 39M |
| 2024 FY Dec 31, 2023 | $129.01M | $129.01M | -$3.16M | $139.80M | $134.19M | 100% | -2.45% | 104.01% | -1.46% | 33.05M |
| 2023 FY Dec 31, 2022 | n/a | $0.00 | -$97.25M | -$93.79M | -$96.67M | n/a | n/a | n/a | -87.78% | 31.29M |
| 2022 FY Dec 31, 2021 | n/a | $0.00 | -$51.13M | -$50.86M | -$55.44M | n/a | n/a | n/a | n/a | 6.27M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $5.34M | sum latest 4 fiscal quarters Revenue | OK | 0001689375-26-000054, 0001689375-25-000050 |
| Revenue Growth TTM | -97.25% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001689375-26-000054, 0001689375-25-000050 |
| Revenue CAGR 3Y | n/a | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | INSUFFICIENT_HISTORY | 0001689375-26-000011 |
| Revenue CAGR 5Y | n/a | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | INSUFFICIENT_HISTORY | 0001689375-26-000011 |
| Gross Profit CAGR 3Y | n/a | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | INSUFFICIENT_HISTORY | 0001689375-26-000011 |
| Operating Income Growth | -682.75% | OperatingIncome_current / OperatingIncome_prior_year - 1 | OK | 0001689375-26-000054, 0001689375-25-000050 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 100% | Gross Profit / Revenue | OK | 0001689375-26-000054, 0001689375-25-000050 |
| Operating Margin | -3,394.53% | Operating Income / Revenue | OK | 0001689375-26-000054, 0001689375-25-000050 |
| ROIC | -51.91% | NOPAT / Average Invested Capital | OK | 0001689375-26-000054, 0001689375-25-000050 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001689375-26-000054 |
| Current Ratio | 10.89x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $0.13 | Revenue / Diluted Shares | OK | 0001689375-26-000054, 0001689375-25-000050 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |